Navigation Links
New Study Provides Benchmarks for Optimizing Marketing Staff Levels to Drive Growth
Date:2/5/2009

CHAPEL HILL, N.C., Feb. 5 /PRNewswire/ -- In today's tough economy, maintaining operational efficiencies remains key, even while focusing on strategy and tactics to drive growth and profitability. In an effort to better understand the resources dedicated by biopharmaceutical companies to support marketing operations, a recent benchmark study was conducted by Best Practices, LLC, with insights available in the newly published report, "Benchmarks for Optimizing Marketing Staff Levels to Drive Growth." Data from this study were collected from more than sixty biopharma marketing leaders.

Benchmark data shares insights from a number of critical areas, including:

-- Staffing and productivity levels utilized across healthcare business models

    -- Growth and profit margin levels across biopharma portfolios
    -- Strategic and tactical activities that drive profitability & growth

The metrics shared in this study, segmented across pharma/biotech, medical devices and generic products, were gathered from across the biopharma industry including such companies as Abbott, Amgen, Baxter, Johnson & Johnson, Novartis, Pfizer, Roche, and Sanofi-Aventis.

    Key metrics found in the report include:
    -- Number of Products Supported Per Tactical Marketing FTE
    -- Number of Strategic Marketing FTEs per $100 Million
    -- Time & Activity Benchmarks for Strategic Marketing Staff
    -- Strategic Marketing Staff Benchmarks Across Key Activities
    -- Tactical Marketing Staff Benchmarks Across Key Activities

For more information on this report, contact Ben Gregory at bgregory@best-in-class.com or (919) 767-9160. To access the full report or download a complimentary copy of the report summary, go to www.best-in-class.com/rr977.htm.

ABOUT BEST PRACTICES, LLC

Best Practices, LLC, conducts work based on the simple yet profound principle that organizations can chart a course to superior economic performance by studying the best business practices, operating tactics and winning strategies of world-class companies. For more than 15 years, our highly credentialed research staff has conducted primary research exclusively for our Fortune 500 client base.


'/>"/>
SOURCE Best Practices, LLC
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Peregrine Pharmaceuticals Bavituximab Achieves Primary Endpoint in First Stage of Phase II Lung Cancer Study
2. Results From Phase 2 Clinical Study of 6R-BH4 in Peripheral Arterial Disease Not Statistically Significant
3. New Study Provides Benchmarks for Winning Brand Team Management
4. New Study Shares Insights for Competitive Intelligence Policies, Ethics and Data Collection
5. New Multi-Center Study Finds Masimo SET Pulse Oximetry Screening Significantly Improves Detection of Congenital Heart Disease in Newborns
6. Epilepsia Study Demonstrates New Add-on Antiepileptic Drug Vimpat(R) (lacosamide) Significantly Reduces Partial-Onset Seizures in Adults With Epilepsy
7. Rib-X Pharmaceuticals Announces Positive Phase 2 Study Results for Delafloxacin and a $25 Million Financing
8. Clinical Research Study Focuses on Little Known Behavioral Changes Related to Parkinsons Disease
9. Cardiovascular Side Effects of Pioglitazone and Rosiglitazone Linked to Vascular and Energy Pathways by Genomas Clinical Study
10. Genomic Health Announces Commencement of QUASAR Clinical Validation Study for Oncotype DX(R) Colon Cancer Assay
11. Pharmasset and Roche Obtain FDA Consent to Start a Phase 2b Study With R7128 in Treatment Naive HCV Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016   EpiBiome , ... secured $1 million in debt financing from Silicon Valley ... up automation and to advance its drug development efforts, ... new facility. "SVB has been an incredible ... the services a traditional bank would provide," said Dr. ...
(Date:6/23/2016)... 23, 2016 Apellis Pharmaceuticals, Inc. today ... trials of its complement C3 inhibitor, APL-2. The ... ascending dose studies designed to assess the safety, ... injection in healthy adult volunteers. Forty ... a single dose (ranging from 45 to 1,440mg) ...
(Date:6/23/2016)... ... June 23, 2016 , ... ClinCapture, ... Pennsylvania Convention Center and will showcase its product’s latest features from June 26 ... presenting a scientific poster on Disrupting Clinical Trials in The Cloud during the ...
(Date:6/23/2016)... PUNE, India , June 23, 2016 /PRNewswire/ ... culture media market research report to its pharmaceuticals ... company profiles, product details and much more. ... market spread across 151 pages, profiling 15 companies ... now available at http://www.reportsnreports.com/reports/601420-global-cell-culture-media-industry-2016-market-research-report.html . ...
Breaking Biology Technology:
(Date:6/16/2016)... , June 16, 2016 ... is expected to reach USD 1.83 billion by ... View Research, Inc. Technological proliferation and increasing demand ... are expected to drive the market growth. ... The development of advanced multimodal techniques ...
(Date:6/7/2016)... June 7, 2016  Syngrafii Inc. and San ... relationship that includes integrating Syngrafii,s patented LongPen™ eSignature ... This collaboration will result in greater convenience for ... union, while maintaining existing document workflow and compliance ... ...
(Date:6/2/2016)... 2, 2016 Perimeter Surveillance & ... Systems, Physical Infrastructure, Support & Other Service  ... offers comprehensive analysis of the global Border ... generate revenues of $17.98 billion in 2016. ... a leader in software and hardware technologies for advanced ...
Breaking Biology News(10 mins):